Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
61.44
-3.22 (-4.98%)
At close: Dec 5, 2025, 4:00 PM EST
62.20
+0.76 (1.24%)
After-hours: Dec 5, 2025, 7:29 PM EST
Arrowhead Pharmaceuticals Revenue
In the fiscal year ending September 30, 2025, Arrowhead Pharmaceuticals had annual revenue of $829.45M with 23,258.15% growth. Arrowhead Pharmaceuticals had revenue of $256.47M in the quarter ending September 30, 2025.
Revenue (ttm)
$829.45M
Revenue Growth
+23,258.15%
P/S Ratio
9.91
Revenue / Employee
$1,166,594
Employees
711
Market Cap
8.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 829.45M | 825.90M | 23,258.15% |
| Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | Pro | Pro | Pro |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ARWR News
- 3 days ago - Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia - Business Wire
- 4 days ago - Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences - Business Wire
- 8 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript - Seeking Alpha
- 9 days ago - Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today - The Motley Fool
- 10 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results - Business Wire
- 11 days ago - Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Business Wire
- 16 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript - Seeking Alpha